Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. 1996

A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

In a blinded, placebo-controlled study, the reactogenicity, immunogenicity, and clinical efficacy of single doses of US inactivated split-virus and Russian live attenuated, cold-adapted influenza vaccines were compared in 555 schoolchildren in Vologda, Russia. Serial serum samples were collected and school absenteeism was assessed. Systemic reactions were rare, but local reactions (primarily erythema at the injection site) were observed in 27% of the inactivated vaccine group, and coryza (12%) and sore throat (8%) were observed in the attenuated vaccine group. At 4 weeks after vaccination a > or = 4-fold rise in titer of hemagglutination inhibition antibody to A (H1N1), A (H3N2), and B was noted, respectively, among 78%, 88%, and 53% of children who received inactivated vaccine and among 55%, 79%, and 30% of children who received attenuated vaccine. The vaccine efficacy for preventing school absenteeism due to respiratory illness during the period of peak influenza activity was 56% for inactivated vaccine and 47% for attenuated vaccine.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006389 Hemagglutinins, Viral Specific hemagglutinin subtypes encoded by VIRUSES. Viral Hemagglutinin,Viral Hemagglutinins,Hemagglutinin, Viral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
September 2021, Cold Spring Harbor perspectives in medicine,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
October 2006, The Pediatric infectious disease journal,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
November 2003, Immunology and allergy clinics of North America,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
July 2021, Virus research,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
January 2011, Journal of the American Pharmacists Association : JAPhA,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
March 2003, The Pediatric infectious disease journal,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
June 2009, Vaccine,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
March 2000, The Journal of infectious diseases,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
August 2009, Vaccine,
A S Khan, and F Polezhaev, and R Vasiljeva, and V Drinevsky, and J Buffington, and H Gary, and A Sominina, and W Keitel, and H Regnery, and N L Lonskaya, and E Doroshenko, and A Gavrilov, and I Ivakhov, and N Arden, and L B Schonberger, and R Couch, and A Kendal, and N Cox
December 1985, The Journal of infectious diseases,
Copied contents to your clipboard!